Evidence map›Paper›PMID 30700416›Full record

ArticleBlood advances2019

Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbα.

Caroline Kardeby, Knut Fälker, Elizabeth J Haining, Maarten Criel, Madelene Lindkvist, Ruben Barroso, Peter Påhlsson, Liza U Ljungberg, Mattias Tengdelius, G Ed Rainger and 8 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Platelet Membrane Receptors and Signalling Pathways.Handbook of experimental pharmacology · 2026
    Review
  4. Article
  5. Using theBrain sciences · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Saccharides fromExperimental and therapeutic medicine · 2022
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 4 countries.

Caroline KardebyCardiovascular Research Centre, School of Medical Sciences, Örebro University, Örebro, Sweden.ORCID 0000-0002-5025-9454
Knut FälkerCardiovascular Research Centre, School of Medical Sciences, Örebro University, Örebro, Sweden.ORCID 0000-0003-2519-203X
Elizabeth J HainingInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0003-1168-5570
Maarten CrielCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Madelene LindkvistCardiovascular Research Centre, School of Medical Sciences, Örebro University, Örebro, Sweden.
Ruben BarrosoInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Peter PåhlssonDivision of Cell Biology, Department of Clinical and Experimental Medicine, and.
Liza U LjungbergCardiovascular Research Centre, School of Medical Sciences, Örebro University, Örebro, Sweden.
Mattias TengdeliusDivision of Organic Chemistry, Linköping University, Linköping, Sweden.
G Ed RaingerInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Stephanie WatsonInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Johannes A EbleInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany; and.
Marc F HoylaertsCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Jonas EmsleyCentre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, The Midlands, United Kingdom.
Peter KonradssonDivision of Organic Chemistry, Linköping University, Linköping, Sweden.
Steve P WatsonInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Yi SunInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Magnus GrenegårdCardiovascular Research Centre, School of Medical Sciences, Örebro University, Örebro, Sweden.ORCID 0000-0002-7003-2169
University of Birmingham · GBÖrebro University · SEKU Leuven · BELinköping University · SEUniversity of Münster · DEUniversity of Nottingham · GB

Funding

British Heart Foundation CH03/003British Heart Foundation FS/14/42/30956British Heart Foundation PG/16/53/32242British Heart Foundation RG/12/7/29693British Heart Foundation RG/13/18/30563
6 · The paper itself

Abstract

Fucoidans are sulfated fucose-based polysaccharides that activate platelets and have pro- and anticoagulant effects; thus, they may have therapeutic value. In the present study, we show that 2 synthetic sulfated α-l-fucoside-pendant glycopolymers (with average monomeric units of 13 and 329) and natural fucoidans activate human platelets through a Src- and phosphatidylinositol 3-kinase (PI3K)-dependent and Syk-independent signaling cascade downstream of the platelet endothelial aggregation receptor 1 (PEAR1). Synthetic glycopolymers and natural fucoidan stimulate marked phosphorylation of PEAR1 and Akt, but not Syk. Platelet aggregation and Akt phosphorylation induced by natural fucoidan and synthetic glycopolymers are blocked by a monoclonal antibody to PEAR1. Direct binding of sulfated glycopolymers to epidermal like growth factor (EGF)-like repeat 13 of PEAR1 was shown by avidity-based extracellular protein interaction screen technology. In contrast, synthetic glycopolymers and natural fucoidans activate mouse platelets through a Src- and Syk-dependent pathway regulated by C-type lectin-like receptor 2 (CLEC-2) with only a minor role for PEAR1. Mouse platelets lacking the extracellular domain of GPIbα and human platelets treated with GPIbα-blocking antibodies display a reduced aggregation response to synthetic glycopolymers. We found that synthetic sulfated glycopolymers bind directly to GPIbα, substantiating that GPIbα facilitates the interaction of synthetic glycopolymers with CLEC-2 or PEAR1. Our results establish PEAR1 as the major signaling receptor for natural fucose-based polysaccharides and synthetic glycopolymers in human, but not in mouse, platelets. Sulfated α-l-fucoside-pendant glycopolymers are unique tools for further investigation of the physiological role of PEAR1 in platelets and beyond.

Indexed as

AnimalsBiopolymersCalciumHumansMiceMice, KnockoutPlatelet AggregationPlatelet Glycoprotein GPIb-IX ComplexPolysaccharidesReceptors, Cell SurfaceSyk Kinaseadhesion receptorBiopolymersCalciumfucoidanPEAR1 protein, humanPEAR1 protein, mousePlatelet Glycoprotein GPIb-IX ComplexPolysaccharidesReceptors, Cell SurfaceSyk KinaseSYK protein, human

Identifiers

PMID30700416
PMCPMC6373755
OpenAlexW2913310538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.